Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Top Cited Papers
- 9 September 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 83 (11), 958-966
- https://doi.org/10.1212/wnl.0000000000000771
Abstract
Objective: To evaluate whether the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant might be effective for migraine prevention. Methods: In this randomized, double-blind, placebo-controlled, multicenter trial (ClinicalTrials.gov NCT00797667), patients experiencing 3–14 migraine days during a 4-week baseline were randomized to telcagepant 140 mg, telcagepant 280 mg, or placebo twice daily for 12 weeks. Efficacy was assessed by mean monthly headache days and migraine/probable migraine days (headache plus ≥1 associated symptom). Results: The trial was terminated following a recommendation from the Safety Monitoring Board due to hepatotoxicity concerns. At termination, the planned 660 patients had been randomized, 656 had been treated with ≥1 dose of study medication, and 14 had completed the trial. The mean treatment duration was 48–50 days. Thirteen patients, all in the telcagepant groups, had an alanine aminotransferase (ALT) elevation ≥3× the upper limit of normal and 7 of these also had an aspartate aminotransferase elevation ≥3× the upper limit of normal. Two patients had very high symptomatic transaminase elevations that occurred within 2–6 weeks of treatment initiation and resolved after treatment discontinuation. The originally planned efficacy analysis over 12 weeks was not performed due to limited data at later time points, but there was evidence that telcagepant resulted in a larger reduction from baseline than placebo for mean monthly headache days (month 1: 140 mg = −2.9, 280 mg = −3.1, placebo = −1.7; p < 0.05) and migraine/probable migraine days (month 1: 140 mg = −2.7, 280 mg = −3.0, placebo = −1.6; p < 0.05). Conclusions: These data suggest a potential role for CGRP receptor antagonism in migraine prophylaxis. However, the observed aminotransferase elevations do not support the use of telcagepant for daily administration. Classification of evidence: This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per month compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.Keywords
This publication has 29 references indexed in Scilit:
- Calcitonin Gene‐Related Peptide (CGRP) and Migraine Current Understanding and State of DevelopmentHeadache: The Journal of Head and Face Pain, 2013
- Long‐Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized TrialHeadache: The Journal of Head and Face Pain, 2010
- Randomized, controlled trial of telcagepant over four migraine attacksCephalalgia, 2010
- Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor AntagonistThe Journal of pharmacology and experimental therapeutics, 2010
- Safety and Tolerability of Short‐Term Preventive Frovatriptan: A Combined AnalysisHeadache: The Journal of Head and Face Pain, 2009
- Randomized, controlled trial of telcagepant for the acute treatment of migraineNeurology, 2009
- Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineNeurology, 2008
- The CGRP-Antagonist, BIBN4096BS Does not Affect Cerebral or Systemic Haemodynamics in Healthy VolunteersCephalalgia, 2005
- Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2004
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990